A M Tang1, N M Graham, R D Semba, A J Saah. 1. Department of Epidemiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: To examine the associations between serum vitamin A and E levels and risk of progression to three key outcomes in HIV-1 infection: first AIDS diagnosis, CD4+ cell decline to < 200 cells x 10(6)/l, and mortality. DESIGN: Non-concurrent prospective study. METHODS: Serum levels of vitamins A and E were measured at the enrollment visit of 311 HIV-seroprevalent homo-/bisexual men participating in the Baltimore/ Washington DC site of the Multicenter AIDS Cohort Study. Cox proportional hazards models were used to estimate the relative hazard of progression to each outcome over the subsequent 9 years, adjusting for several independent covariates. RESULTS: Men in the highest quartile of serum vitamin E levels (> or = 23.5 mumol/l) showed a 34% decrease in risk of progression to AIDS compared with those in the lowest quartile [relative hazard (RH), 0.66; 95% confidence interval (CI), 0.41-1.06)]. This effect was statistically significant when comparing the highest quartile of serum vitamin E to the remainder of the cohort (RH, 0.67; 95% CI, 0.45-0.98). Associations between serum vitamin A levels and risk of progression to AIDS were less clear, but vitamin A levels were uniformly in the normal to high range (median = 2.44 mumol/l). Similar trends were observed for each vitamin with mortality as the outcome, but neither vitamin was associated with CD4+ cell decline to < 200 cells x 10(6)/l. Men who reported current use of multivitamin or single vitamin E supplements had significantly higher serum tocopherol levels than those who were not taking supplements (P = 0.0001). Serum retinol levels were unrelated to intake of multivitamin or single vitamin A supplements. CONCLUSIONS: These data suggest that high serum levels of vitamin E may be associated with slower HIV-1 disease progression, but no relationship was observed between retinol levels and disease progression in this vitamin A-replete population.
OBJECTIVE: To examine the associations between serum vitamin A and E levels and risk of progression to three key outcomes in HIV-1 infection: first AIDS diagnosis, CD4+ cell decline to < 200 cells x 10(6)/l, and mortality. DESIGN: Non-concurrent prospective study. METHODS: Serum levels of vitamins A and E were measured at the enrollment visit of 311 HIV-seroprevalent homo-/bisexual men participating in the Baltimore/ Washington DC site of the Multicenter AIDS Cohort Study. Cox proportional hazards models were used to estimate the relative hazard of progression to each outcome over the subsequent 9 years, adjusting for several independent covariates. RESULTS:Men in the highest quartile of serum vitamin E levels (> or = 23.5 mumol/l) showed a 34% decrease in risk of progression to AIDS compared with those in the lowest quartile [relative hazard (RH), 0.66; 95% confidence interval (CI), 0.41-1.06)]. This effect was statistically significant when comparing the highest quartile of serum vitamin E to the remainder of the cohort (RH, 0.67; 95% CI, 0.45-0.98). Associations between serum vitamin A levels and risk of progression to AIDS were less clear, but vitamin A levels were uniformly in the normal to high range (median = 2.44 mumol/l). Similar trends were observed for each vitamin with mortality as the outcome, but neither vitamin was associated with CD4+ cell decline to < 200 cells x 10(6)/l. Men who reported current use of multivitamin or single vitamin E supplements had significantly higher serum tocopherol levels than those who were not taking supplements (P = 0.0001). Serum retinol levels were unrelated to intake of multivitamin or single vitamin A supplements. CONCLUSIONS: These data suggest that high serum levels of vitamin E may be associated with slower HIV-1 disease progression, but no relationship was observed between retinol levels and disease progression in this vitamin A-replete population.
Authors: Valerie L Flax; Linda S Adair; Lindsay H Allen; Setarah Shahab-Ferdows; Daniela Hampel; Charles S Chasela; Gerald Tegha; Eric J Daza; Amanda Corbett; Nicole L Davis; Deborah Kamwendo; Athena P Kourtis; Charles M van der Horst; Denise J Jamieson; Margaret E Bentley Journal: J Nutr Date: 2015-07-08 Impact factor: 4.798
Authors: Thomas R Ziegler; Grace A McComsey; Jennifer K Frediani; Erin C Millson; Vin Tangpricha; Allison Ross Eckard Journal: AIDS Res Hum Retroviruses Date: 2014-07-16 Impact factor: 2.205
Authors: Harry L June; Andrew Rong Song Tzeng Yang; Joseph L Bryant; Odell Jones; Walter Royal Journal: J Neurovirol Date: 2009-09 Impact factor: 2.643
Authors: Francis A Obuseh; Pauline E Jolly; Yi Jiang; Faisal M B Shuaib; John Waterbor; William O Ellis; Chandrika J Piyathilake; Renee A Desmond; Evans Afriyie-Gyawu; Timothy D Phillips Journal: Int J Vitam Nutr Res Date: 2010-12 Impact factor: 1.784
Authors: Min Li-Weber; Markus A Weigand; Marco Giaisi; Dorothee Süss; Monika K Treiber; Sven Baumann; Elena Ritsou; Raoul Breitkreutz; Peter H Krammer Journal: J Clin Invest Date: 2002-09 Impact factor: 14.808
Authors: Sheila Isanaka; Ferdinand Mugusi; Claudia Hawkins; Donna Spiegelman; James Okuma; Said Aboud; Chalamilla Guerino; Wafaie W Fawzi Journal: JAMA Date: 2012-10-17 Impact factor: 56.272
Authors: Kosuke Kawai; Roland Kupka; Ferdinand Mugusi; Said Aboud; James Okuma; Eduardo Villamor; Donna Spiegelman; Wafaie W Fawzi Journal: Am J Clin Nutr Date: 2009-11-25 Impact factor: 7.045
Authors: John R Koethe; Benjamin H Chi; Karen M Megazzini; Douglas C Heimburger; Jeffrey S A Stringer Journal: Clin Infect Dis Date: 2009-09-01 Impact factor: 9.079